Work carried out at Queen's Veterinary School Hospital, University of Cambridge, Madingley Road, Cambridge CB3 0ES, UK.
COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy
Article first published online: 6 SEP 2010
© 2010 Blackwell Publishing Ltd
Veterinary and Comparative Oncology
Volume 9, Issue 2, pages 141–148, June 2011
How to Cite
Belshaw, Z., Constantio-Casas, F., Brearley, M. J., Dunning, M. D., Holmes, M. A. and Dobson, J. M. (2011), COX-2 expression and outcome in canine nasal carcinomas treated with hypofractionated radiotherapy. Veterinary and Comparative Oncology, 9: 141–148. doi: 10.1111/j.1476-5829.2010.00243.x
This work was presented at the Veterinary Cancer Society 29th Annual Conference, Texas, October 2009.
- Issue published online: 16 MAY 2011
- Article first published online: 6 SEP 2010
- COX-2 expression;
The expression of cyclooxygenase isoform 2 (COX-2) in canine nasal carcinomas has been well documented. COX-2 expression has proven to be a prognostic factor in several human tumours. The aims of this study were to assess the correlation between immunohistochemical COX-2 expression and prognosis using rhinoscopic biopsies from 42 dogs with nasal carcinomas treated with hypofractionated radiotherapy, and to establish a replicable COX-2 scoring system. Ninety per cent of sections evaluated were COX-2 positive with a mean score of 6.6 (median 8.0; range 0–12). Neither COX-2 expression nor tumour type had a significant correlation with survival. There are likely to be many as yet unidentified variants which contribute to length of survival in dogs with nasal carcinomas. Immunohistochemical COX-2 expression appears unlikely to be of prognostic significance for canine nasal carcinoma.